Prime Therapeutics gives us a peek at its drug trend, via a press release. Maybe a full report will follow. (Prime Release) Prime is owned by a number of Blue Cross Blue Shield plans and they represent most of its customer base. It is currently probably the fourth largest PBM by number of people served, almost 20 million, and has a very extensive commercial business. It says it had a 2.5% increase in drug spending in 2016 (unclear if this is on a per capita basis). Specialty drug spending rose 13.7%, while traditional drug trend was a negative 1.7%. The company claims its various management tools saved clients $2.2 billion. Use of generics rose from an already high 83.1% in 2015 to 84.7% in 2016. Prime also highlighted growing use of preferred pharmacies and continued emphasis on certain diseases and drug categories. Diabetes and biologic anti-inflammatory drugs were highlighted as a major source of greater spending. Diabetes drugs account for 13% of all medication spending, and rose 18% on the back of a 10% increase in price and 6% increase in utilization. A care management program used by Prime was said to have reduced the trend to 7.5%. Anti-inflammatory drugs used for arthritis and other diseases accounted for 10% of all drug spending and 40% of specialty drug expenses in 2016. Prime noted its efforts to manage specialty drug spend across the medical and pharmacy benefits, which can be important as many infused and other specialty drugs end up being paid for outside of pharmacy benefits.
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
October 2, 2023
Coronamonomania Lives Forever, Part 226
Once more into the research breach, lockdowns, masks, et al.
Commentary
October 1, 2023
More Climate Research that the Hysterics Won’t Like
A few climate notes as the truth-tellers somehow manage to penetrate that attempted censorship of…
Commentary
October 1, 2023
Coronamonomania Lives Forever, Part 225
Interesting research continues to appear and I will keep summarizing it for you.